Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. (FRA:FDY)

FRA:FDY Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Operating Revenue	711.63	709.4	850.73	1,031	1,140	832.47
Other Revenue	-	-	-	-	0.5	1.34
Revenue	711.63	709.4	850.73	1,031	1,140	833.8
Revenue Growth (YoY)	2.89%	-16.61%	-17.50%	-9.57%	36.76%	-18.99%
Cost of Revenue	73.43	63.46	74.08	86.29	81.02	66.09
Gross Profit	638.2	645.95	776.66	944.87	1,059	767.72
Selling, General & Admin	439.74	341.04	426.45	599.5	660.26	475.71
Research & Development	322.45	314.16	243.76	226.85	224.39	139.27
Other Operating Expenses	17.51	7.44	5.39	6.84	6.15	4.08
Operating Expenses	743.26	653.7	699.5	830.78	896.57	624.97
Operating Income	-105.06	-7.75	77.15	114.09	162.72	142.74
Interest Expense	-0.69	-0.59	-3.07	-1.54	-1.06	-5.6
Interest & Investment Income	3.22	5.55	7.97	11.29	25.89	23.36
Currency Exchange Gain (Loss)	0.15	0.15	-1.08	-0.83	0.14	-0.3
Other Non Operating Income (Expenses)	-0.31	-0.05	-0.42	-0.14	6.21	-6.7
EBT Excluding Unusual Items	-102.69	-2.69	80.56	122.88	193.91	153.5
Gain (Loss) on Sale of Investments	-10.41	-10.41	-4.35	-1.28	-	-
Gain (Loss) on Sale of Assets	0.1	0.03	0.3	1.92	1.78	4.6
Asset Writedown	-3.99	-3.93	-5	-1.83	-2.15	-0.83
Other Unusual Items	22.38	22.46	26.02	10.61	22.38	19.43
Pretax Income	-94.61	5.46	97.53	132.29	215.92	176.7
Income Tax Expense	-31.74	-33.98	-10.92	-4.98	3.54	12.44
Earnings From Continuing Operations	-62.87	39.43	108.45	137.27	212.38	164.26
Minority Interest in Earnings	0.2	0.3	0.18	0.72	0.92	0.4
Net Income	-62.67	39.73	108.63	138	213.3	164.66
Net Income to Common	-62.67	39.73	108.63	138	213.3	164.66
Net Income Growth	-	-63.42%	-21.28%	-35.30%	29.54%	-27.58%
Shares Outstanding (Basic)	824	1,037	1,034	1,030	1,041	989
Shares Outstanding (Diluted)	824	1,037	1,034	1,031	1,045	989
Shares Change (YoY)	-24.84%	0.23%	0.29%	-1.29%	5.59%	7.20%
EPS (Basic)	-0.08	0.04	0.11	0.13	0.20	0.17
EPS (Diluted)	-0.08	0.04	0.11	0.13	0.20	0.17
EPS Growth	-	-63.51%	-19.19%	-35.00%	20.17%	-32.44%
Free Cash Flow	99.3	-59.18	-27.95	77.96	148.78	70.59
Free Cash Flow Per Share	0.12	-0.06	-0.03	0.08	0.14	0.07
Dividend Per Share	0.030	0.050	0.070	0.070	0.070	0.050
Dividend Growth	-66.67%	-28.57%	-	-	40.00%	-28.57%
Gross Margin	89.68%	91.05%	91.29%	91.63%	92.90%	92.07%
Operating Margin	-14.76%	-1.09%	9.07%	11.06%	14.27%	17.12%
Profit Margin	-8.81%	5.60%	12.77%	13.38%	18.70%	19.75%
Free Cash Flow Margin	13.95%	-8.34%	-3.29%	7.56%	13.05%	8.47%
EBITDA	-50.38	45.74	129.05	186.92	216.5	191.62
EBITDA Margin	-7.08%	6.45%	15.17%	18.13%	18.99%	22.98%
D&A For EBITDA	54.68	53.49	51.89	72.83	53.78	48.88
EBIT	-105.06	-7.75	77.15	114.09	162.72	142.74
EBIT Margin	-14.76%	-1.09%	9.07%	11.06%	14.27%	17.12%
Effective Tax Rate	-	-	-	-	1.64%	7.04%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.